IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v48y2025i8d10.1007_s40264-025-01535-8.html
   My bibliography  Save this article

Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database

Author

Listed:
  • Raffaella Napoli

    (University of Campania “Luigi Vanvitelli”
    University of Campania “Luigi Vanvitelli”
    Université de Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team)

  • Christophe Richez

    (Centre Hospitalier Universitaire
    CNRS-UMR 5164, ImmunoConcept, Université de Bordeaux)

  • Cristina Scavone

    (University of Campania “Luigi Vanvitelli”
    University of Campania “Luigi Vanvitelli”
    Link Campus University)

  • Allison Singier

    (Université de Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team)

  • Maxime Demourgues

    (CHU de Bordeaux, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance Bordeaux-DROM)

  • Annamaria Mascolo

    (University of Campania “Luigi Vanvitelli”
    University of Campania “Luigi Vanvitelli”
    Link Campus University)

  • Annalisa Capuano

    (University of Campania “Luigi Vanvitelli”
    University of Campania “Luigi Vanvitelli”)

  • Francesco Salvo

    (Université de Bordeaux, INSERM, Bordeaux Population Health, U1219, AHeaD Team
    CHU de Bordeaux, Service de Pharmacologie Médicale, Centre Régional de Pharmacovigilance Bordeaux-DROM)

Abstract

Background Rheumatoid arthritis (RA) is commonly treated with Janus kinase inhibitors (JAKis) and anti-tumor necrosis factor-α (anti-TNFα), but the cardiovascular safety profiles of these drugs remain unclear. Objective The aim of this study was to describe the individual case safety reports of major adverse cardiac events (MACE) or stroke and to determine whether there was a difference in the frequency of reporting of cardiovascular events between JAKis and anti-TNFα used in RA. Methods A case/non-case study was conducted using the WHO VigiBase® database. Descriptive analysis was performed, the time to onset (TTO) of MACE was calculated, and the reporting odds ratio (ROR) was used to estimate the frequency of MACE reports associated with JAKis versus anti-TNFα in RA. Results A total of 18,099 cases of MACE were identified, of which 2543 (14%) were associated with JAKis, predominantly in women (65.4%) and in patients aged ≥65 years (49.9%). The median time to onset was 210 days (IQR 60–510) for JAKis and 690 days (210–1460) for anti-TNFα. JAKis were associated with higher odds of reporting MACE (ROR 1.38 [95% CI 1.32–1.44]), mainly due to non-fatal stroke (1.65 [1.55–1.75]). Stroke as a whole showed similar results (1.62 [1.53–1.72]). The ROR of MACE was also slightly increased in patients aged

Suggested Citation

  • Raffaella Napoli & Christophe Richez & Cristina Scavone & Allison Singier & Maxime Demourgues & Annamaria Mascolo & Annalisa Capuano & Francesco Salvo, 2025. "Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database," Drug Safety, Springer, vol. 48(8), pages 943-952, August.
    • Handle: RePEc:spr:drugsa:v:48:y:2025:i:8:d:10.1007_s40264-025-01535-8
    DOI: 10.1007/s40264-025-01535-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-025-01535-8
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-025-01535-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:48:y:2025:i:8:d:10.1007_s40264-025-01535-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.